Acrocomia aculeata associated with doxorubicin: cardioprotection and anticancer activity

Doxorubicin (Dox) is a chemotherapeutic agent widely used in the clinic, whose side effects include cardiotoxicity, associated with decreased antioxidant defenses and increased oxidative stress. The association of Dox natural antioxidants can extend its use if not interfering pharmacological potential. In this study, we aimed to understand mechanisms aqueous extract Acrocomia aculeata leaves (EA-Aa) cancer cells co-treatment Dox, vitro vivo models. It was found that EA-Aa showed relevant decrease viability (K562 MCF-7) apoptosis death. cytotoxic effect cells. therapeutic also promoted change cell death, leading higher rate compared group, which induced necrosis. addition, non-cancer cells, enhanced red blood (RBC) redox state lower hemolysis malondialdehyde (MDA) content had no nor toxicity. Furthermore, protection against Dox-induced cytotoxicity H9c2 (cardiomyoblast), partially mediated by NRF2 pathway. , treatment MDA levels heart, kidney, brain, evaluated C57Bl/6 mice cardiotoxicity Dox. Together, our results proved effectiveness potentiating anticancer effects, cardioprotective activity, suggesting as potential adjuvant.